Physician profile
John M Feigert
NPI 1033174560
$3,730.80
in general payments reported to CMS, 2019-2025
17 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $29.07 · 2021: $1,074 · 2022: $172 · 2023: $185 · 2024: $1,732 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,180 · Food and Beverage: $966 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Food and Beverage | $966.12 |
| Education | $132.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,438.83 | 2019-2024 | |
| Janssen Biotech, INC. | $1,338.03 | 2020-2025 | Tecvayli, Talvey, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $137.77 | 2022-2023 | Opdivo |
| Pfizer INC. | $110.09 | 2019-2025 | |
| Gilead Sciences, INC. | $109.09 | 2024 | Trodelvy |
| Adc Therapeutics America, INC. | $103.73 | 2024 | |
| Abbvie INC. | $90.72 | 2024 | |
| Daiichi Sankyo INC. | $89.39 | 2024-2025 | Enhertu, Injectafer |
| Incyte Corporation | $59.99 | 2019 | |
| Celgene Corporation | $53.27 | 2022-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $40.84 | 2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $38.78 | 2019-2023 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $32.81 | 2023 | Libtayo |
| Rigel Pharmaceuticals, INC. | $25.89 | 2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $21.63 | 2025 | Tukysa, Mektovi, Braftovi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.00 | 2019 | |
| Seagen INC. | $18.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feigert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.